



Collier, D. A. et al. (2021) Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. *Nature*, 593(7857), pp. 136-141.

(doi: [10.1038/s41586-021-03412-7](https://doi.org/10.1038/s41586-021-03412-7))

This is the Author Accepted Manuscript.

There may be differences between this version and the published version. You are advised to consult the publisher's version if you wish to cite from it.

<http://eprints.gla.ac.uk/237431/>

Deposited on: 21 March 2021

# Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies

Dami A. Collier<sup>1,2,3,18</sup>, Anna De Marco<sup>4,18</sup>, Isabella A.T.M. Ferreira<sup>1,2,18</sup>, Bo Meng<sup>1,2,18</sup>, Rawlings Datir<sup>1,2,3,18</sup>, Alexandra C. Walls<sup>5</sup>, Steven A. Kemp<sup>1,2,3</sup>, Jessica Bassi<sup>4</sup>, Dora Pinto<sup>4</sup>, Chiara Silacci Fregni<sup>4</sup>, Siro Bianchi<sup>4</sup>, M. Alejandra Tortorici<sup>5</sup>, John Bowen<sup>5</sup>, Katja Culap<sup>4</sup>, Stefano Jaconi<sup>4</sup>, Elisabetta Cameroni<sup>4</sup>, Gyorgy Snell<sup>6</sup>, Matteo S. Pizzuto<sup>4</sup>, Alessandra Franzetti Pellanda<sup>7</sup>, Christian Garzoni<sup>7</sup>, Agostino Riva<sup>8</sup>, The CITIID-NIHR BioResource COVID-19 Collaboration, Anne Elmer<sup>9</sup>, Nathalie Kingston<sup>10</sup>, Barbara Graves<sup>10</sup>, Laura E. McCoy<sup>3</sup>, Kenneth G. C. Smith<sup>1,2</sup>, John R. Bradley<sup>2,10</sup>, Nigel Temperton<sup>11</sup>, L. Lourdes Ceron-Gutierrez<sup>12</sup>, Gabriela Barcenas-Morales<sup>12,13</sup>, The COVID-19 Genomics UK (COG-UK) consortium, William Harvey<sup>14</sup>, Herbert W. Virgin<sup>6</sup>, Antonio Lanzavecchia<sup>4</sup>, Luca Piccoli<sup>4</sup>, Rainer Doffinger<sup>12,15</sup>, Mark Wills<sup>2</sup>, David Veessler<sup>5</sup>, Davide Corti<sup>4,18\*</sup>, Ravindra K. Gupta<sup>1,2,15,16,17,18\*</sup>

<sup>1</sup>Cambridge Institute of Therapeutic Immunology & Infectious Disease, Cambridge, UK. <sup>2</sup>Department of Medicine, University of Cambridge, Cambridge, UK. <sup>3</sup>Division of Infection and Immunity, University College London, London, UK. <sup>4</sup>Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. <sup>5</sup>Department of Biochemistry, University of Washington, Seattle, WA, USA. <sup>6</sup>Vir Biotechnology, San Francisco, CA, USA. <sup>7</sup>Clinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, Lugano, Switzerland. <sup>8</sup>Division of Infectious Diseases, Luigi Sacco Hospital, University of Milan, Milan, Italy. <sup>9</sup>NIHR Cambridge Clinical Research Facility, Cambridge, UK. <sup>10</sup>NIHR Bioresource, Cambridge, UK. <sup>11</sup>University of Kent, Canterbury, UK. <sup>12</sup>Department of Clinical Biochemistry and Immunology, Addenbrooke's Hospital, Cambridge, UK. <sup>13</sup>Laboratorio de Inmunologia, S-Cuautitlán, UNAM, Mexico. <sup>14</sup>Institute of Biodiversity, University of Glasgow, Glasgow, UK. <sup>15</sup>Department of Haematology, University of Cambridge, Cambridge, UK. <sup>16</sup>University of KwaZulu Natal, Durban, South Africa. <sup>17</sup>Africa Health Research Institute, Durban, South Africa. <sup>18</sup>These authors contributed equally: Dami A. Collier, Anna De Marco, Isabella A. T. M. Ferreira, Bo Meng, Rawlings Datir, Davide Corti, Ravindra K. Gupta.

\* e-mail: dcorti@vir.bio; rkg20@cam.ac.uk

## Abstract

SARS-CoV-2 transmission is uncontrolled in many parts of the world, compounded in some areas by higher transmission potential of the B.1.1.7 variant<sup>1</sup> now reported in 94 countries. It is unclear whether responses to SARS-CoV-2 vaccines based on the prototypic strain will be impacted by mutations found in B.1.1.7. Here we assessed<sup>2</sup> immune responses following vaccination with mRNA-based vaccine BNT162b<sup>2</sup>. We measured neutralising antibody responses following first and second immunisations using pseudoviruses expressing the wild-type Spike protein or the 8 amino acid mutations found in the B.1.1.7 spike protein. The vaccine sera exhibited a broad range of neutralising titres against the wild-type pseudoviruses that were modestly reduced against B.1.1.7 variant. This reduction was also evident in sera from some convalescent patients. Decreased B.1.1.7 neutralisation was also observed with monoclonal antibodies targeting the N-terminal domain (9 out of 10), the RBM (5 out of 31), but not in RBD neutralising mAbs binding outside the RBM. Introduction of the E484K mutation in a B.1.1.7 background to reflect a newly emergent Variant of Concern (VOC 202102/02) led to a more substantial loss of neutralising activity by vaccine-elicited antibodies and mAbs (19 out of 31) over that conferred by the B.1.1.7 mutations alone. E484K emergence on a B.1.1.7 background represents a threat to the vaccine BNT162b.

## Background

The mRNA BNT162b2 vaccine encodes the full-length trimerised S protein of SARS CoV-2<sup>2</sup>, designed against the Wuhan-1 isolate. Concerns have been raised as to whether vaccines will be effective against newly emergent SARS-CoV-2 variants, such as B.1.1.7 (N501Y.V1). In clinical studies of BNT162b2, geometric mean titre (GMT) rose after first dose with high levels of protection against infection and severe disease after the second dose<sup>3</sup>.

## Results

Thirty-seven participants had received the first dose of the BNT162b2 mRNA vaccine three weeks prior to blood draw for serum and peripheral blood mononuclear cells (PBMC) collection. Median age was 62 years (IQR 47-84) and 35% were female. Twenty-one of these participants also had a blood draw 3 weeks after receiving the second dose of BNT162b2 mRNA vaccine. Serum IgG titres to

Nucleocapsid (N) protein, S and the S receptor binding domain (RBD) were assayed (Extended Data Fig. 1a).

Using lentiviral pseudotyping we studied WT (wild type bearing D614G) and mutant B.1.1.7 S proteins (Fig. 1a) in order to measure neutralisation activity of vaccine-elicited sera. The vaccine sera exhibited a range of inhibitory dilutions giving 50% neutralisation (ID50) (Fig. 1b, c). The GMT against wild type (WT) following the second dose of vaccine was substantially higher than after the first dose (318 vs 77) (Fig. 1b–e). There was correlation between total Spike IgG titres and serum neutralisation titres (Extended Data Fig. 1b). A broad range of T cell responses was measured by IFN gamma FluoroSpot against SARS-CoV-2 peptides in vaccinees after first dose. These cellular responses did not correlate with serum neutralisation titres or IgG S antibody titres (Extended Data Fig. 1c–d).

We then generated mutated pseudoviruses carrying S protein with mutations N501Y, A570D and the H69/V70 deletion. We observed a small increase in the ability of sera from vaccinees and convalescent individuals to inhibit this triple mutant virus (Extended Data Fig. 2a, b, 2c). We next completed the full set of eight mutations in the S protein present in B.1.1.7 variant (Fig. 1a). 20/29 of those with neutralisation activity after first dose showed evidence of a reduction in B.1.1.7 neutralisation titres (Fig. 1b, c, Extended Data Fig. 3), with mean fold change of 3.2 (SD 5.7). Following the second dose, GMT was markedly increased compared with first dose titres, with mean fold change 1.9 (SD 0.9) (Fig. 1d, e). Amongst sera from 27 recovered individuals, the GMT at 50% neutralisation was 1334 for WT, significantly higher than post second dose vaccination (Fig. 1f, g). The fold change in ID50 for neutralisation of B.1.1.7 versus wild type (D614G) was 4.5 (Fig. 1f, g and Extended Data Fig. 4).

The E484K substitution (Fig. 2a) has been reported as an escape mutation for several monoclonal antibodies<sup>4</sup>, and is present in the B.1.351 (501Y.V2) and P.1 (501Y.V3) lineages. As of 11th of February 2021, thirty B.1.1.7 sequences also had the E484K substitution (Fig. 2c). Phylogenetic analysis suggests that there have been multiple independent acquisitions, with one lineage appearing to expand over time, indicating active transmission (Fig. 2b). This has resulted in Public Health England naming this as a variant of concern (VOC 202102/02)<sup>5</sup>. We therefore generated pseudoviruses bearing B.1.1.7 spike mutations with or without additional E484K and tested these against sera obtained after first and second dose mRNA vaccine as well as against convalescent sera. Following second dose, we observed a significant loss of neutralising activity for the pseudovirus with B.1.1.7 spike mutations and E484K (Fig. 3d, e). The mean fold change for the E484K B.1.1.7 Spike was 6.7 compared to 1.9 for B.1.1.7, relative to WT (Fig. 3a–c, Extended Data Fig. 5). Similarly, when we tested a panel of convalescent sera with a range of neutralisation titres (Fig. 1f, g, Extended Data Fig. 5), we observed additional loss of activity against the mutant B.1.1.7 spike with E484K, with fold change of 11.4 relative to WT (Fig. 3f, g, Extended Data Fig. 5).

### **B.1.1.7 monoclonal antibody sensitivity**

We tested 60 mAbs isolated from 15 individuals that recovered from SARS-CoV-2 infection in early 2020 with an in-vitro pseudotyped neutralisation assay against B.1.1.7 spike (Supplementary Table 1). 20 out of 60 (33.3%) mAbs showed a greater than 2-fold loss of neutralising activity of B.1.1.7 variant compared to WT SARS-CoV-2 (Fig. 4a, b and Extended Data Fig. 6). B.1.1.7 mutant virus fully escaped neutralisation by 8 out of 10 NTD-targeting mAbs (80%) (Fig. 4c). Of the 31 RBM-targeting mAbs, 5 (16.1%) showed more than 100-fold decrease in B.1.1.7 neutralisation, and additional 6 mAbs (19.4%) had a partial 2-to-10-fold reduction (Fig. 4d). Finally, all RBD-specific non-RBM-targeting mAbs tested fully retained B.1.1.7 neutralising activity (Fig. 4e).

To address the role of B.1.1.7 N501Y mutation in the neutralisation escape from RBM-specific antibodies, we tested the binding of 50 RBD-specific mAbs to WT and N501Y mutant RBD by biolayer interferometry (Fig. 4f and Extended Data Fig. 7). The 5 RBM-specific mAbs that failed to neutralise B.1.1.7 variant (Fig. 4d) showed a complete loss of binding to N501Y RBD mutant (Fig. 4g, h), demonstrating a role for this mutation as an escape mechanism for certain RBM-targeting mAbs.

To assess the effect of E484K on this panel of mAbs we generated a SARS-CoV-2 pseudotype carrying the K417N, E484K and N501Y mutations (TM). The inclusion of the K417N substitution was prompted by the observation that substitutions at this position have been found in 5 sequences from recent viral isolates within the B.1.1.7 lineage (K417 to N, E or R). This is in keeping with convergent evolution of the virus towards an RBD with N501Y, E484K and K417N/T as evidenced by B.1.351 and P.1 lineages. Importantly, mutations at K417 are reported to escape neutralisation from mAbs, including the recently approved mAb LY-CoV016<sup>4,6</sup>. Out of the 60 mAbs tested, 20 (33.3%) showed >10-fold loss of neutralising activity of TM mutant compared to WT SARS-CoV-2 (Fig. 4a, b and Extended Data Fig. 6), and of these 19 are RBM-specific mAbs. As above, we addressed the role of E484K mutation in escape from RBM-specific antibodies, by testing the binding of 50 RBD-specific mAbs to WT and E484K mutant RBD by biolayer interferometry (Fig. 4f and Extended Data Fig. 8). Out of the 19 RBM-specific mAbs that showed reduced or loss of neutralisation of TM mutant (Fig. 4d), 16 showed a complete or partial loss of binding to E484K RBD mutant (Fig. 4g, h), consistent with findings that E484K is an important viral escape mutation<sup>7,8,39</sup>. Three of these 16 mAbs also lost binding to an RBD carrying N501Y, indicating that a fraction of RBM antibodies is sensitive to both N501Y and E484K mutations. Similarly, three of the 19 mAbs that lost neutralisation of TM mutant (S2D8, S2H7 and S2X128) were previously shown to lose binding and neutralisation to the K417V mutant, and here shown to be sensitive to either N501Y or E484K mutations

### **B.1.1.7 RBD binding to ACE2**

Using biolayer interferometry, we found that ACE2 bound to the B.1.1.7 RBD with an affinity of 22 nM compared to 133 nM for the WT RBD (Extended Data Fig. 9), in agreement with our previous deep mutational scanning measurements using dimeric ACE2<sup>9</sup>. Although ACE2 bound with comparable on-rates to both RBDs, the observed dissociation rate constant was slower for B.1.1.7 than for the WT RBD (Extended data Table 1). These findings might participate in the efficient ongoing transmission of this newly emergent SARS-CoV-2 lineage, and possibly reduced opportunity for antibody binding. To understand the impact of TM mutations (K417N, E484K and N501Y), we evaluated binding of ACE2 to the immobilized TM RBD. We determined an ACE2 binding affinity of 64 nM for the TM RBD, driven by a faster off-rate than observed for the B.1.1.7 RBD but slower than for the WT RBD. We propose that the K417N mutation is slightly detrimental to ACE2 binding explaining the intermediate affinity determined for the TM RBD compared to the B.1.1.7 and WT RBDs, likely as a result of disrupting the salt bridge formed with ACE2 residue D30.

## **Discussion**

Serum neutralising activity is a correlate of protection for other respiratory viruses, including influenza<sup>10</sup> and respiratory syncytial virus where prophylaxis with monoclonal antibodies has been used in at-risk groups<sup>11,12</sup>. Neutralising antibody titres appeared to be highly correlated with vaccine protection against SARS-CoV-2 rechallenge in non-human primates<sup>13,14</sup>.

This study reports on the neutralisation by sera collected after both the first and second doses of the BNT162b2 vaccine. The participants of this study were older adults, in line with the targeting of this age group in the initial rollout of the vaccination campaign in the UK. We demonstrated that a pseudovirus bearing S protein with the full set of mutations present in the B.1.1.7 variant did result in small reduction in neutralisation by sera from vaccinees that was more marked following the first dose than the second dose. This could be related to increased breadth/potency/concentration of antibodies following the boost dose. Other studies have reported a small reduction of neutralisation against the B.1.1.7 variant from individuals vaccinated with two doses of BNT162b215 and mRNA-1273<sup>16</sup>. The reduced neutralising activity observed with polyclonal antibodies elicited by mRNA vaccines observed in this study is further supported by the loss of neutralising activity observed with human mAbs directed to both RBD and, to a major extent, to NTD.

Multiple variants, including the 501Y.V2 and B.1.1.7 lineages, harbour multiple mutations as well as deletions in NTD, most of which are located in a site of vulnerability that is targeted by all known

NTD-specific neutralising antibodies<sup>17,18</sup>. The role of NTD-specific neutralising antibodies might be under-estimated, in part by the use of neutralisation assays based on target cells over-expressing ACE2 receptors. NTD-specific mAbs were suggested to interfere with viral entry based on other accessory receptors, such as DC-SIGN and L-SIGN<sup>19</sup>, and their neutralisation potency was found to be dependent on different in vitro culture conditions<sup>17</sup>. The observation that 9 out of 10 NTD-specific neutralising antibodies failed to show a complete or near-complete loss of neutralising activity against B.1.1.7 indicates that this new variant may have also evolved to escape from this class of antibodies, that may have a yet unrecognized role in protective immunity. Taken together, the presence of multiple escape mutations in NTD is supportive of the hypothesis that this region of the spike, in addition to RBM, is also under immune pressure.

Worryingly, we have shown that there are multiple B.1.1.7 sequences in the UK bearing E484K with early evidence of transmission as well as independent acquisitions. We measured further reduction in neutralisation titres by vaccine sera when E484K was present alongside the B.1.1.7 S mutations. Wu and co-authors<sup>16</sup> have also shown that variants carrying the E484K mutation resulted in a 3-to-6-fold reduction in neutralisation by sera from mRNA-1273 vaccinated individuals. Consistently, in this study we found that approximately 50% of the RBM mAbs tested lost neutralising activity against SARS-CoV-2 carrying E484K. E484K has been shown to impact neutralisation by monoclonal antibodies or convalescent sera, especially in combination with N501Y and K417N<sup>7,20-23</sup>.

Vaccines are a key part of a long-term strategy to bring SARS-CoV-2 transmission under control. Our data suggest that vaccine escape to current Spike directed vaccines designed against the Wuhan strain will be inevitable, particularly given that E484K is emerging independently and recurrently on a B.1.1.7 (501Y.V1) background and given the rapid global spread of B.1.1.7. Other major variants with E484K such as 501Y.V2 and V3 are also spreading regionally. This should be mitigated by designing next generation vaccines with mutated S sequences and using alternative viral antigens.

## Methods

**Participant recruitment and ethics** Participants who had received the first dose of vaccine and individuals with COVID-19 (Coronavirus Disease-19) were consented into the COVID-19 cohort of the NIHR Bioresource. The study was approved by the East of England – Cambridge Central Research Ethics Committee (17/EE/0025).

**SARS-CoV-2 serology by multiplex particle-based flow cytometry (Luminex)** Recombinant SARS-CoV-2 N, S and RBD were covalently coupled to distinct carboxylated bead sets (Luminex; Netherlands) to form a 3-plex and analyzed as previously described (Xiong et al. 2020). Specific binding was reported as mean fluorescence intensities (MFI). Linear regression was used to explore the association between antibody response, T cell response and serum neutralisation in Stata 13. The Pearson correlation coefficient was reported.

**Generation of S mutants** Amino acid substitutions were introduced into the D614G pCDNA<sub>2</sub>-SARS-CoV-2\_S plasmid as previously described<sup>24</sup> using the QuikChange Lightning Site-Directed Mutagenesis kit, following the manufacturer's instructions (Agilent Technologies, Inc., Santa Clara, CA). Sequences were checked by Sanger sequencing.

Preparation of B.1.1.7 or TM SARS-CoV-2 S glycoprotein-encoding-plasmid used to produce SARS-CoV-2-MLV based on overlap extension PCR. Briefly, a modification of the overlap extension PCR protocol<sup>25</sup> was used to introduce the nine mutations of the B.1.1.7 lineage or the three mutations in TM mutant in the SARS-CoV-2 S gene. In a first step, 9 DNA fragments with overlap sequences were amplified by PCR from a plasmid (pCMV1, Genlantis) encoding the full-length SARS-CoV-2 S gene (BetaCoV/Wuhan-Hu-1/2019, accession number mn908947). The mutations (del-69/70, del-144, N501Y, A570D, D614G, P681H, S982A, T716I and D1118H or K417N, E484K and N501Y) were introduced by amplification with primers with similar Tm. Deletion of the C-terminal 21 amino acids was introduced to increase surface expression of the recombinant S<sup>26</sup>. Next, 3 contiguous

overlapping fragments were fused by a first overlap PCR (step 2) using the utmost external primers of each set, resulting in 3 larger fragments with overlapping sequences. A final overlap PCR (step 3) was performed on the 3 large fragments using the utmost external primers to amplify the full-length S gene and the flanking sequences including the restriction sites KpnI and NotI. This fragment was digested and cloned into the expression plasmid pCMV1. For all PCR reactions the Q5 Hot Start High fidelity DNA polymerase was used (New England Biolabs Inc.), according to the manufacturer's instructions and adapting the elongation time to the size of the amplicon. After each PCR step the amplified regions were separated on agarose gel and purified using Illustra GFX™ PCR DNA and Gel Band Purification Kit (Merck KGaA).

**Pseudotype virus preparation** Viral vectors were prepared by transfection of 293T cells by using Fugene HD transfection reagent (Promega). 293T cells were transfected with a mixture of 11ul of Fugene HD, 1µg of pCDNAD19spike-HA, 1ug of p8.91 HIV-1 gag-pol expression vector<sup>27,28</sup>, and 1.5µg of pCSFLW (expressing the firefly luciferase reporter gene with the HIV-1 packaging signal). Viral supernatant was collected at 48 and 72h after transfection, filtered through 0.45µm filter and stored at -80°C. The 50% tissue culture infectious dose (TCID50) of SARS-CoV-2 pseudovirus was determined using Steady-Glo Luciferase assay system (Promega).

Serum/plasma pseudotype neutralization assay Spike pseudotype assays have been shown to have similar characteristics as neutralisation testing using fully infectious wild type SARS-CoV-2<sup>29</sup>. Virus neutralisation assays were performed on 293T cell transiently transfected with ACE2 and TMPRSS2 using SARS-CoV-2 spike pseudotyped virus expressing luciferase<sup>30</sup>. Pseudotyped virus was incubated with serial dilution of heat inactivated human serum samples or sera from vaccinees in duplicate for 1h at 37°C. Virus and cell only controls were also included. Then, freshly trypsinized 293T ACE2/TMPRSS2 expressing cells were added to each well. Following 48h incubation in a 5% CO<sub>2</sub> environment at 37 °C, luminescence was measured using the Steady-Glo or Bright-Glo Luciferase assay system (Promega). Neutralization was calculated relative to virus only controls. Dilution curves were presented as a mean neutralization with standard error of the mean (SEM). ID50 values were calculated in GraphPad Prism. The ID50 within groups were summarised as a geometric mean titre and statistical comparison between groups were made with Wilcoxon ranked sign test. In addition, the impact of the mutations on the neutralising effect of the sera were expressed as fold change (FC) of ID50 of the wild-type compared to mutant pseudotyped virus. Statistical difference in the mean FC between groups was determined using a 2-tailed t-test.

**IFN $\gamma$  FluoroSpot assays** Frozen PBMCs were rapidly thawed, and the freezing medium was diluted into 10ml of TexMACS media (Miltenyi Biotech), centrifuged and resuspended in 10ml of fresh media with 10U/ml DNase (Benzonase, Merck-Millipore via Sigma-Aldrich), PBMCs were incubated at 37 °C for 1h, followed by centrifugation and resuspension in fresh media supplemented with 5% Human AB serum (Sigma Aldrich) before being counted. PBMCs were stained with 2ul of each antibody: anti-CD3-fluorescein isothiocyanate (FITC), clone UCHT1; anti-CD4-phycoerythrin (PE), clone RPA-T4; anti-CD8a-peridinin-chlorophyll protein - cyanine 5.5 (PerCP Cy5.5), clone RPA-8a (all BioLegend, London, UK), LIVE/DEAD Fixable Far Red Dead Cell Stain Kit (Thermo Fisher Scientific). PBMC phenotyping was performed on the BD Accuri C6 flow cytometer. Data were analysed with FlowJo v10 (Becton Dickinson, Wokingham, UK). 1.5 to 2.5 x 10<sup>5</sup> PBMCs were incubated in pre-coated Fluorospot plates (Human IFN $\gamma$  FLUOROSPOT (Mabtech AB, Nacka Strand, Sweden)) in triplicate with peptide mixes specific for Spike, Nucleocapsid and Membrane proteins of SARS-CoV-2 (final peptide concentration 1µg/ml/peptide, Miltenyi Biotech) and an unstimulated and positive control mix (containing anti-CD3 (Mabtech AB), Staphylococcus Enterotoxin B (SEB), Phytohaemagglutinin (PHA) (all Sigma Aldrich)) at 37 °C in a humidified CO<sub>2</sub> atmosphere for 48 hours. The cells and medium were decanted from the plate and the assay developed following the manufacturer's instructions. Developed plates were read using an AID iSpot reader (Oxford Biosystems, Oxford, UK) and counted using AID EliSpot v7 software (Autoimmun Diagnostika GmbH, Strasberg, Germany). All data were then corrected for background cytokine production and

expressed as spot forming units (SFU)/Million PBMC or CD3 T cells. The association between spike Tcell response, spike specific antibody response and serum neutralisation was determined using linear regression and the Pearson correlation coefficient between these variables were determined using Stata 13.

**Ab discovery and recombinant expression** Human mAbs were isolated from plasma cells or memory B cells of SARS-CoV or SARS-CoV-2 immune donors, as previously described<sup>31–34</sup>. Recombinant antibodies were expressed in ExpiCHO cells at 37 °C and 8% CO<sub>2</sub>. Cells were transfected using ExpiFectamine. Transfected cells were supplemented 1 day after transfection with ExpiCHO Feed and ExpiFectamine CHO Enhancer. Cell culture supernatant was collected eight days after transfection and filtered through a 0.2 µm filter. Recombinant antibodies were affinity purified on an ÄKTA xpress FPLC device using 5 mL HiTrap<sup>TM</sup> MabSelect<sup>TM</sup> Prisma columns followed by buffer exchange to Histidine buffer (20 mM Histidine, 8% sucrose, pH 6) using HiPrep 26/10 desalting columns.

**MAbs pseudovirus neutralization assay** MLV-based SARS-CoV-2 S-glycoprotein-pseudotyped viruses were prepared as previously described (Pinto et al., 2020). HEK293T/17cells were cotransfected with a WT, B.1.1.7 or TM SARS-CoV-2 spike glycoprotein-encoding-plasmid, an MLV Gag-Pol packaging construct and the MLV transfer vector encoding a luciferase reporter using X-tremeGENE HP transfection reagent (Roche) according to the manufacturer's instructions. Cells were cultured for 72 h at 37 °C with 5% CO<sub>2</sub> before harvesting the supernatant. VeroE6 stably expressing human TMPRSS2 were cultured in Dulbecco's Modified Eagle's Medium (DMEM) containing 10% fetal bovine serum (FBS), 1% penicillin–streptomycin (100 I.U. penicillin/mL, 100 µg/mL), 8 µg/ml puromycin and plated into 96-well plates for 16–24 h. Pseudovirus with serial dilution of mAbs was incubated for 1 h at 37 °C and then added to the wells after washing 2 times with DMEM. After 2–3 h DMEM containing 20% FBS and 2% penicillin–streptomycin was added to the cells. Following 48–72 h of infection, Bio-Glo (Promega) was added to the cells and incubated in the dark for 15 min before reading luminescence with Synergy H1 microplate reader (BioTek). Measurements were done in duplicate and relative luciferase units were converted to percent neutralization and plotted with a non-linear regression model to determine IC<sub>50</sub> values using GraphPad PRISM software (version 9.0.0).

Antibody binding measurements using bio-layer interferometry (BLI) Mabs (Supplementary Table 1) were diluted to 3 µg/ml in kinetic buffer (PBS supplemented with 0.01% BSA) and immobilized on Protein A Biosensors (FortéBio). Antibody-coated biosensors were incubated for 3 mins with a solution containing 5 µg/ml of WT, N501Y or E484K SARS-CoV-2 RBD in kinetic buffer, followed by a 3-min dissociation step. Change in molecules bound to the biosensors caused a shift in the interference pattern that was recorded in real time using an Octet RED96 system (FortéBio). The binding response over time was used to calculate the area under the curve (AUC) using GraphPad PRISM software (version 9.0.0)

**Production of SARS-CoV-2 and B.1.1.7 receptor binding domains and human ACE2.** The SARS-CoV-2 RBD (BEI NR-52422) construct was synthesized by GenScript into CMVR with an N-terminal mu-phosphatase signal peptide and a C-terminal octa-histidine tag (GHHHHHHH) and an avi tag. The boundaries of the construct are N<sub>328</sub>RFPN<sub>331</sub>-C<sup>35</sup>. The B.1.1.7 RBD gene was synthesized by GenScript into pCMVR with the same boundaries and construct details with a mutation at N501Y. These plasmids were transiently transfected into Expi293F cells using Expi293F expression medium (Life Technologies) at 37 °C 8% CO<sub>2</sub> rotating at 150 rpm. The cultures were transfected using PEI cultivated for 5 days. Supernatants were clarified by centrifugation (10 min at 4000xg) prior to loading onto a nickel-NTA column (GE). Purified protein was biotinylated overnight using BirA (Biotin ligase) prior to size exclusion chromatography (SEC) into phosphate buffered saline (PBS). Human ACE2-Fc (residues 1–615 with a C-terminal thrombin cleavage site and human Fc tag) were synthesized by Twist. Clarified supernatants were affinity purified using a Protein A column (GE LifeSciences) directly neutralized and buffer exchanged. The Fc tag was removed by thrombin

cleavage in a reaction mixture containing 3 mg of recombinant ACE2-FC ectodomain and 10 µg of thrombin in 20 mM Tris-HCl pH8.0, 150 mM NaCl and 2.5 mM CaCl<sub>2</sub>. The reaction mixture was incubated at 25 °C overnight and re-loaded on a Protein A column to remove uncleaved protein and the Fc tag. The cleaved protein was further purified by gel filtration using a Superdex 200 column 10/300 GL (GE Life Sciences) equilibrated in PBS.

**Protein affinity measurement using bio-layer interferometry.** Biotinylated RBD (WT, N501Y, or TM) were immobilized at 5 ng/µL in undiluted 10X Kinetics Buffer (Pall) to SA sensors until a load level of 1.1nm. A dilution series of either monomeric ACE2 or Fab in undiluted kinetics buffer starting at 1000-50nM was used for 300-600 seconds to determine protein-protein affinity. The data were baseline subtracted and the plots fitted using the Pall FortéBio/Sartorius analysis software (version 12.0). Data were plotted in Prism.

**Phylogenetic analysis.** All complete and low coverage excluded SARS-CoV-2 sequences were downloaded from the GISAID database (<http://gisaid.org/>)<sup>36</sup> on 11th February 2021. All sequences were realigned to the SARS-CoV-2 reference strain MN908947.3, using MAFFT v7.475 with automatic flavour 37 selection and the --keeplength --addfragments options. Sequences were then deduplicated. Major SARS-CoV-2 clade memberships were assigned to all sequences using the Nextclade server v0.12 (<https://clades.nextstrain.org/>).

Maximum likelihood phylogenetic trees were produced using the above curated dataset using IQ-TREE v2.1.2<sup>38</sup>. Evolutionary model selection for trees were inferred using ModelFinder<sup>39</sup> and trees were estimated using the GTR+F+I model with 1000 ultrafast bootstrap<sup>40</sup>. All trees were visualised using Figtree v.1.4.4 (<http://tree.bio.ed.ac.uk/software/figtree/>) and manipulated and coloured with ggtree v2.2.4. Phylogenies were rooted on the SARS-CoV-2 reference sequence (MN908947.r) and nodes arranged in descending order.

**Statistical analysis** Linear regression was used to explore the association between antibody response, T cell response and serum neutralisation in Stata 13. The Pearson correlation coefficient was reported.

**Neutralisation data analysis** Neutralisation was calculated relative to virus only controls. Dilution curves were presented as a mean neutralization with standard error of the mean (SEM). IC50 values were calculated in GraphPad Prism. The inhibitory dilution (ID50) within groups were summarised as a geometric mean titre and statistical comparison between groups were made with Wilcoxon ranked sign test. In addition, the impact of the mutations on the neutralising effect of the sera were expressed as fold change of ID50 of the wild-type compared to mutant pseudotyped virus. Statistical difference in the mean FC between groups was determined using a 2-tailed t-test.

**For antibody level IFNy FluoroSpot assay data analysis.** The association between spike Tcell response, spike specific antibody response and serum neutralisation was determined using linear regression and the Pearson correlation coefficient between these variables were determined using Stata 13.

**Data availability.** The neutralization and BLI data shown in Fig. 4 and Extended Data Figs. 6–8 can be found in Source Data for Fig. 4. All sequences are publicly available and were downloaded from <http://gisaid.org>. Deduplicated and subsampled data are freely available at [https://github.com/StevenKemp/sequence\\_files/blob/main/vaccinepaper/with\\_background\\_subsampled\\_deduped\\_aligned\\_UKonly\\_484\\_vui.fasta.gz](https://github.com/StevenKemp/sequence_files/blob/main/vaccinepaper/with_background_subsampled_deduped_aligned_UKonly_484_vui.fasta.gz). Other data are available from the corresponding authors on request.

**Acknowledgements** We would like to thank Cambridge University Hospitals NHS Trust Occupational Health Department. We would also like to thank the NIHR Cambridge Clinical Research Facility and staff at CUH and. We would like to thank Eleanor Lim and Georgina Okecha. We thank Dr James Voss for the kind gift of HeLa cells stably expressing ACE2. RKG is supported by a Wellcome Trust Senior Fellowship in Clinical Science (WT108082AIA). LEM is supported by a Medical Research Council

Career Development Award (MR/R008698/1). SAK is supported by the Bill and Melinda Gates Foundation via PANGEA grant: OPP1175094. DAC is supported by a Wellcome Trust Clinical PhD Research Fellowship. KGCS is the recipient of a Wellcome Investigator Award (200871/Z/16/Z). This research was supported by the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre, the Cambridge Clinical Trials Unit (CCTU), and the NIHR BioResource. This study was supported by the National Institute of General Medical Sciences (R01GM120553 to D.V.), the National Institute of Allergy and Infectious Diseases (DP1AI158186 and HHSN272201700059C to D.V.), a Pew Biomedical Scholars Award (D.V.), an Investigators in the Pathogenesis of Infectious Disease Awards from the Burroughs Wellcome Fund (D.V.) and Fast Grants (D.V.). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. JAGB is supported by the Medical Research Council (MC\_UP\_1201/16). IATMF is funded by a SANTHE award (DEL-15-006).

## References

1. Volz, E. et al. Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data. medRxiv, 2020.2012.2030.20249034, <https://doi.org/10.1101/2020.12.30.20249034> (2021).
2. Mulligan, M. J. et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. *Nature* 586, 589-593, <https://doi.org/10.1038/s41586-020-2639-4> (2020).
3. Polack, F. P. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med* 383, 2603-2615, <https://doi.org/10.1056/NEJMoa2034577> (2020).
4. Wang, P. et al. Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization. bioRxiv, <https://doi.org/10.1101/2021.01.25.428137> (2021).
5. PHE. Public Health England statement on Variant of Concern and new Variant Under Investigation, <<https://www.gov.uk/government/news/phe-statement-on-variant-of-concern-and-new-variant-under-investigation>> (2021).
6. Thomson, E. C. et al. Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. *Cell*, <https://doi.org/10.1016/j.cell.2021.01.037> (2021).
7. Greaney, A. J. et al. Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies. *Cell host & microbe*, <https://doi.org/10.1016/j.chom.2021.02.003> (2021).
8. Andreano, E. et al. SARS-CoV-2 escape *in vitro* from a highly neutralizing COVID-19 convalescent plasma. bioRxiv, 2020.2012.2028.424451, <https://doi.org/10.1101/2020.12.28.424451> (2020).
9. Starr, T. N. et al. Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding. *Cell* 182, 1295-1310 e1220, <https://doi.org/10.1016/j.cell.2020.08.012> (2020).
10. Verschoor, C. P. et al. Microneutralization assay titres correlate with protection against seasonal influenza H1N1 and H3N2 in children. *PloS one* 10, e0131531, <https://doi.org/10.1371/journal.pone.0131531> (2015).
11. Kulkarni, P. S., Hurwitz, J. L., Simoes, E. A. F. & Piedra, P. A. Establishing Correlates of Protection for Vaccine Development: Considerations for the Respiratory Syncytial Virus Vaccine Field. *Viral Immunol* 31, 195-203, <https://doi.org/10.1089/vim.2017.0147> (2018).
12. Goddard, N. L., Cooke, M. C., Gupta, R. K. & Nguyen-Van-Tam, J. S. Timing of monoclonal antibody for seasonal RSV prophylaxis in the United Kingdom. *Epidemiol Infect* 135, 159-162, <https://doi.org/10.1017/S0950268806006601> (2007).
13. Mercado, N. B. et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. *Nature* 586, 583-588, <https://doi.org/10.1038/s41586-020-2607-z> (2020).
14. McMahan, K. et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. *Nature*, <https://doi.org/10.1038/s41586-020-03041-6> (2020).
15. Muik, A. et al. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera. *Science*, <https://doi.org/10.1126/science.abg6105> (2021).
16. Wu, K. et al. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants

- from global SARS-CoV-2 variants. *bioRxiv*, <https://doi.org/10.1101/2021.01.25.427948> (2021). 17.
- McCallum, M. et al. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. *bioRxiv*, <https://doi.org/10.1101/2021.01.14.426475> (2021).
18. Suryadevara, N. et al. Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein. *bioRxiv*, 2021.2001.2019.427324, <https://doi.org/10.1101/2021.01.19.427324> (2021).
19. Soh, W. T. et al. The N-terminal domain of spike glycoprotein mediates SARS-CoV-2 infection by associating with L-SIGN and DC-SIGN. *bioRxiv*, 1-30, <https://doi.org/10.1101/2020.11.05.369264> (2020).
20. Tegally, H. et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. *medRxiv*, 2020.2012.2021.20248640, <https://doi.org/10.1101/2020.12.21.20248640> (2020).
21. Greaney, A. J. et al. Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies. *bioRxiv*, 2020.2012.2031.425021, <https://doi.org/10.1101/2020.12.31.425021> (2021).
22. Greaney, A. J. et al. Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition. *Cell Host & Microbe* (2020).
23. Weisblum, Y. et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. *Elife* 9, e61312, <https://doi.org/10.7554/eLife.61312> (2020).
24. Gregson, J. et al. HIV-1 viral load is elevated in individuals with reverse transcriptase mutation M184V/I during virological failure of first line antiretroviral therapy and is associated with compensatory mutation L74I. *Journal of Infectious Diseases* (2019).
25. Forloni, M., Liu, A. Y. & Wajapeyee, N. Creating Insertions or Deletions Using Overlap Extension Polymerase Chain Reaction (PCR) Mutagenesis. *Cold Spring Harb Protoc* 2018, <https://doi.org/10.1101/pdb.prot097758> (2018).
26. Case, J. B. et al. Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2. *Cell Host Microbe* 28, 475-485 e475, <https://doi.org/10.1016/j.chom.2020.06.021> (2020).
27. Naldini, L., Blomer, U., Gage, F. H., Trono, D. & Verma, I. M. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. *Proc Natl Acad Sci U S A* 93, 11382-11388, <https://doi.org/10.1073/pnas.93.21.11382> (1996).
28. Gupta, R. K. et al. Full length HIV-1 gag determines protease inhibitor susceptibility within in vitro assays. *AIDS* 24, 1651 (2010).
29. Schmidt, F. et al. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. 2020.2006.2008.140871, <https://doi.org/10.1101/2020.06.08.140871> *bioRxiv* (2020).
30. Mlcochova, P. et al. Combined point of care nucleic acid and antibody testing for SARS-CoV-2 following emergence of D614G Spike Variant. *Cell Rep Med*, 100099, <https://doi.org/10.1016/j.xcrm.2020.100099> (2020).
31. Corti, D. et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. *Science* 333, 850-856, <https://doi.org/10.1126/science.1205669> (2011).
32. Pinto, D. et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. *Nature* 583, 290-295, <https://doi.org/10.1038/s41586-020-2349-y> (2020).
33. Tortorici, M. A. et al. Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. *Science* 4, eabe3354-3316, <https://doi.org/10.1126/science.abe3354> (2020).
34. Piccoli, L. et al. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology. *Cell*, 1-55, <https://doi.org/10.1016/j.cell.2020.09.037> (2020).

35. Walls, A. C. et al. Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2. *Cell* 183, 1367-1382 e1317, <https://doi.org/10.1016/j.cell.2020.10.043> (2020).
36. Shu, Y. & McCauley, J. GISAID: Global initiative on sharing all influenza data - from vision to reality. *Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin* 22, 30494, <https://doi.org/10.2807/1560-7917.ES.2017.22.13.30494> (2017).
37. Katoh, K. & Standley, D. M. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. *Mol Biol Evol* 30, 772-780, <https://doi.org/10.1093/molbev/mst010> (2013).
38. Minh, B. Q. et al. IQ-TREE 2: New Models and Efficient Methods for Phylogenetic Inference in the Genomic Era. *Mol Biol Evol* 37, 1530-1534, <https://doi.org/10.1093/molbev/msaa015> (2020).
39. Kalyanamoorthy, S., Minh, B. Q., Wong, T. K. F., von Haeseler, A. & Jermin, L. S. ModelFinder: fast model selection for accurate phylogenetic estimates. *Nat Methods* 14, 587-589, <https://doi.org/10.1038/nmeth.4285> (2017).
40. Minh, B. Q., Nguyen, M. A. & von Haeseler, A. Ultrafast approximation for phylogenetic bootstrap. *Mol Biol Evol* 30, 1188-1195, <https://doi.org/10.1093/molbev/mst024> (2013).

**Fig. 1) Neutralization by first and second dose mRNA vaccine sera against wild type and B.1.1.7 Spike mutant SARS-CoV-2 pseudotyped viruses.** a, Spike in open conformation with a single erect RBD (PDB: 6ZGG) in trimer axis vertical view with the locations of mutated residues highlighted in red spheres and labelled on the monomer with erect RBD. Vaccine first dose (b-c, n=37), second dose (d-e, n=21) and convalescent sera, Conv. (f-g, n=27) against WT and B.1.1.7 Spike mutant with N501Y, A570D, ΔH69/V70, Δ144/145, P681H, T716I, S982A and D1118H. GMT with s.d presented of two independent experiments with two technical repeats. Wilcoxon matched-pairs signed rank test. Two-tailed p-values \*<0.05, \*\*<0.01, \*\*\*\*<0.0001; ns not significant. No adjustment for multiple comparisons. HS – human Ab serum control. Limit of detection for 50% neutralisation set at 10. GMT: geometric mean titre for 50% neutralisation.

**Fig. 2) E484K appearing in background of B.1.1.7 with evidence of transmission.** a. Representation of Spike RBM:ACE2 interface (PDB: 6M0J) with residues E484, N501 and K417 highlighted as spheres coloured by element b. Maximum likelihood phylogeny of a subset of sequences from the United Kingdom bearing the E484K mutation (green) and lineage B.1.1.7 (blue), with background sequences without RBD mutations in black. As of 11th Feb 2021, 30 sequences from the B.1.1.7 lineage (one cluster of 25 at top of phylogenetic tree) have acquired the E484K mutation (red). c. Sequence accumulation over time in GISAID for UK sequences with B.1.1.7 and E484K. RBD – receptor binding domain; NTD – N terminal domain.

**Fig. 3) Neutralization potency of mRNA vaccine sera and convalescent sera (pre SARS-CoV-2 B.1.1.7) against pseudotyped virus bearing Spike mutations in the B1.1.7 lineage with and without E484K in the receptor binding domain (all In Spike D614G background).** a, Example neutralization curves for vaccinated individuals. Data points represent mean of technical replicates with standard error and are representative of two independent experiments (b-g). 50% neutralisation titre for each virus against sera derived (b,c, n=37) following first vaccination (d,e, n=21) following second vaccination and (f,g, n=20) convalescent sera (CS) expressed as fold change relative to WT. Data points are mean fold change of technical replicates and are representative of two independent experiments. Central bar represents mean with outer bars representing s.d. Error bars for negative values are not shown. Paired T-test. Two-tailed p-values \*<0.05, \*\*<0.01, \*\*\*\*<0.0001; ns not significant. Limit of detection for 50% neutralization set at 10.

**Fig. 4) Neutralization and binding by a panel of NTD- and RBD-specific mAbs against WT, B.1.1.7 and RBD mutant SARS-CoV-2 viruses.** **a**, Neutralization of WT D614G (black), B.1.1.7 (blue) and a triple mutant (TM, carrying RBD mutations K417N/E484K/N501Y) (red) pseudotyped SARS-CoV-2-MLVs by 3 selected mAbs (S2E12, S2X333 and S2H14) from one representative experiment. Shown is the mean  $\pm$  s.d. of 2 technical replicates. **b**, Neutralization of WT (D614G), B.1.1.7 and TM SARS-CoV-2-MLVs by 60 mAbs targeting NTD (n=10), RBM (n=31) and non-RBM sites in the RBD (n=19). Shown are the mean IC<sub>50</sub> values (ng/ml) of n=2 independent experiments. **c-e**, Neutralization shown as mean IC<sub>50</sub> values (upper panel) and mean fold change of B.1.1.7 (blue) or TM (red) relative to WT (lower panel) of NTD (**c**), RBM (**d**) and non-RBM (**e**) mAbs. Upper panel shows mean IC<sub>50</sub> values  $\pm$  s.d from 2 independent experiments. Lower panel shows mean fold change  $\pm$  s.d from 2 independent experiments. **f-h**, Kinetics of binding of mAbs to WT (black), N501Y (blue) and E484K (red) RBD as measured by bio-layer interferometry (BLI). Shown in (**f**) are the 4 RBM-targeting mAbs with no reduced binding to N501Y or E484K RBD. Area under the curve (AUC) (**g**) and AUC fold change (**h**) of 50 mAbs tested against WT, N501Y and E484K RBD. mAbs with a >1.3 AUC fold change shown in blue and red. mAbs: monoclonal antibodies. NTD: N- terminal domain.